Charles S. Berkman
2019 - Ligand Pharmaceuticals
Compensation breakdown
| Non-Equity Incentive Plan | $136,933 |
|---|---|
| Option Awards | $722,777 |
| Salary | $427,620 |
| Stock Awards | $733,290 |
| Other | $6,547 |
| Total | $2,027,167 |
Berkman received $733.3K in stock awards, accounting for 36% of the total pay in 2019.
Berkman also received $136.9K in non-equity incentive plan, $722.8K in option awards, $427.6K in salary and $6.5K in other compensation.
Rankings
In 2019, Charles S. Berkman's compensation ranked 5,850th out of 13,971 executives tracked by ExecPay. In other words, Berkman earned more than 58.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,850 out of 13,971 | 58th |
Division Manufacturing | 2,193 out of 5,695 | 62nd |
Major group Chemicals And Allied Products | 793 out of 2,194 | 64th |
Industry group Drugs | 668 out of 1,880 | 65th |
Industry Pharmaceutical Preparations | 492 out of 1,392 | 65th |
Pay ratio
| Charles S. Berkman's Pay | $2,027,167 |
|---|---|
| Median Employee's Pay | $109,795 |
| Pay Ratio | 18to 1 |
In 2019, the annual total compensation of Charles S. Berkman was $2,027,167.
The annual total compensation of the median employee at Ligand Pharmaceuticals was $109,795.
The ratio of Charles S. Berkman's pay to the pay of median employee was therefore 18 to one.
Berkman's colleagues
We found three more compensation records of executives who worked with Charles S. Berkman at Ligand Pharmaceuticals in 2019.